The updated, revised edition of this acclaimed book offers authoritative guidance on trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting and hereditary prostate cancer.

The thoroughly updated and revised third edition of Management of Prostate Cancer provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. Highlighting the latest major advances in the field, the book ** includes chapters on the most controversial areas of prostate cancer screening, chemoprevention, and active surveillance; updated chapters on genetic risk and progression, biopsy schemes, treatment of complications, and comparative treatment outcomes for surgery; and new chapters on risk factors, new markers, nomograms, and focal therapy. This volume also features overviews of new and emerging drugs and treatment paradigms for castrate resistant disease, advances that promise to extend life and perhaps even cure a subset of men with metastatic disease.

With its comprehensive illustrations and contributions from renowned experts in the field, Management of Prostate Cancer, 3 rd Edition is an invaluable resource for practitioners in the treatment of prostate cancer.

Focuses on the full spectrum of disease from current molecular and genetic hypotheses regarding risk and progression Authors will represent a broad spectrum of opinion and expertise in the prostate cancer community Provide an updated, concise overview of major themes and controversies in the epidemiology, diagnosis, and management of prostate cancer

Autorentext

Eric A. Klein, MD
Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH, USA

J. Stephen Jones, MD
Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH, USA

Zusammenfassung
The thoroughly updated and revised third edition of Management of Prostate Cancer provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer.

Inhalt

Epidemiology and Risk Factors.- Twenty years and counting: is PSA still useful in 2010?.- Prostate Cancer Screening: A Review of the Evidence with Clinical Practice Implications.- Beyond PSA: Promising New Markers for Prostate Cancer.- Hereditary Prostate Cancer and Genetic Risk.- Prostate Inflammation and Prostate Cancer.- Molecular Progression of Prostate Cancer: Androgens and Estrogens.- The Role of Obesity and Diet in Prostate Cancer.- Prostate Cancer Risk Reduction by Chemoprevention.- Current Issues in Pathologic Evaluation.- Optimum Prostate Biopsy: Technique and Strategies.- The Utility of Nomograms in Routine Clinical Practice.- Active Surveillance Comes of Age.- Focal Therapy: Prostate Hemiablation as the First Historical Treatment Model for Focal Therapy of Early Stage Prostate Cancer.- Contemporary External Beam Radiotherapy.- Surgery, Brachytherapy, or External Beam Radiation for Low and Intermediate-Risk Disease?.- The Role for Radical Prostatectomy in Advanced Prostate Cancer.- Radiation Therapy in the Management of Locally Advanced Prostate Cancer.- Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer.- Treatment Modalities of Post-Prostatectomy Incontinence: A Historical Perspective As Well As Current Therapy Options.- Management of Biochemical Recurrence After Localized Treatment for Prostate Cancer.- Management of Newly Diagnosed Metastatic Disease.- Pitfalls of Androgen Deprivation Therapy.- Current Management of Castration-resistant Prostate Cancer (CRPC).- Radiopharmaceuticals and Bone Metastasis.